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Abstract
The incidence of heart failure (HF) is increasing because of aging of the popula-
tion. Despite optimal therapy, patients with HF experience disease progression 
associated with high mortality rates. HF is still the first cause of hospital admission 
in subjects aged >65 years. The obvious solution for HF epidemics is to prevent 
new-onset HF with therapies directed specifically to mechanistic targets that are 
involved in the transition to HF. The mineralocorticoid receptor (MR) and its natu-
ral ligand, the hormone aldosterone (Aldo), play important roles during cardiac and 
arterial remodeling, but the underlying effects are still not understood. MR antago-
nists are highly recommended for treatment of systolic symptomatic HF. However, 
adverse effects limit their use in clinical practice. Galectin-3 (Gal-3), neutrophil 
gelatinase-associated lipocalin (NGAL), and cardiotrophin-1 (CT-1) have been 
identified as highly focused targets controlling downstream key MR-mediated 
HF mechanisms. Therefore, interfering with mechanistic pathways involved in 
downstream MR activation may provide therapeutic alternatives to MR antagonists. 
The aim of this review is to focus on the role of the MR biotargets in cardiovascular 
remodeling.
Keywords: biotarget, galectin-3, neutrophil gelatinase-associated lipocalin, 
cardiotrophin-1
1. Introduction
Inappropriate mineralocorticoid signaling has been shown to play an important 
role in the progression of cardiovascular disease. Aldosterone (Aldo) is a main 
regulator of renal sodium reabsorption with an overall effect on volemia and blood 
pressure. Aldo binds to the mineralocorticoid receptor (MR), which works as a 
transcription factor of the nuclear receptor family present in the kidney and also 
in various other non-epithelial cells including the heart and the vasculature [1]. 
Indeed, new extrarenal pathophysiological effects of this hormone have been char-
acterized, extending its actions to the cardiovascular system [2]. A growing body 
of clinical and preclinical evidence suggests that Aldo and MR play an important 
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pathophysiological role in cardiovascular remodeling by promoting changes involv-
ing cardiac hypertrophy, fibrosis, arterial stiffness, as well as in inflammation and 
oxidative stress [3]. In line with these findings, inappropriate MR activation has 
been shown to promote cardiovascular remodeling in experimental models [4]. The 
RALES, EPHESUS, and the EMPHASIS-HF clinical trials demonstrated that the 
addition of MR antagonists (MRAs) to standard care markedly reduced the overall 
and cardiovascular mortality in patients with systolic heart failure (HF) [5–7]. The 
beneficial effects were mainly associated with a reduction of cardiovascular fibro-
sis, as assessed by circulating biomarkers of cardiovascular extracellular matrix [8]. 
Moreover, results of the recently completed REMINDER (impact of eplerenone 
on CV outcomes in patients post myocardial infarction, clinical trial number 
NCT01176968) trial and TOPCAT (NCT00094302) trial suggest that MR blockade 
might be clinically beneficial, respectively, for acute myocardial infarction healing 
and progression of HF with preserved ejection fraction.
The molecular targets involved in the remodeling processes modulated by 
Aldo/MR activation in the cardiovascular system need to be more precisely ana-
lyzed. Inflammatory processes are tightly linked with fibrosis during cardiovas-
cular remodeling. In addition to profibrotic targets, there is evidence that Aldo/
MR may trigger inflammatory processes negatively impacting on cardiovascular 
remodeling processes. Thus, MR activation and inhibition modulate the expres-
sion of several pro-inflammatory molecules that may contribute to the patho-
genesis of cardiovascular remodeling: Aldo/MR activation increases monocyte 
chemoattractant protein-1 (CCL-2), transforming growth factor-β1 (TGF-β1), 
connective tissue growth factor (CTGF), plasminogen activator inhibitor type-1 
(PAI-1), as well as collagen and metalloproteases through MR-dependent mecha-
nisms. The identification of the Aldo/MR-modulated targets in cardiovascular 
remodeling associated with HF development is actually a medical need. Their 
inhibition could add therapeutic benefits in patients at high risk for the develop-
ment of HF and cardiovascular remodeling. In the last years, new candidates to be 
Aldo/MR biotargets emerged in preclinical and clinical studies, such as galectin-3 
(Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), and cardiotrophin-1 
(CT-1) (Figure 1).
Figure 1. 
Aldo/MR biotargets Gal-3, NGAL, and CT-1 contribute to cardiovascular remodeling and dysfunction in 
various pathological and clinical conditions.
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2. Galectin-3
2.1 Galectin-3 induces fibrosis, inflammation, and oxidative stress
Galectin-3 (Gal-3) is a 29–35 kDa protein, member of a β-galactoside-binding 
lectin family, localized in the nucleus, cytoplasm, cell surface, and extracellular 
space [9]. It is composed of a highly conserved N-terminal domain and a C-terminal 
carbohydrate recognition domain, which interacts with glycoproteins [10]. The 
damaging effects of Gal-3 have been associated with its capacity to bind matrix 
proteins such as cell surface receptors (integrins), collagen, elastin, or fibronectin 
[11]. The expression of this lectin has been reported in many tissues, including the 
heart, vessels, and kidney [12]. Moreover, Gal-3 is expressed in many cell types of 
the cardiovascular system such as cardiac fibroblasts [13], vascular smooth muscle 
cells [14], endothelial cells [15], and inflammatory cells [16]. Gal-3 is involved in 
numerous physiological and pathological processes, some of which, inflamma-
tion and fibrosis, are pivotal contributing to pathophysiological mechanisms in 
the development and progression of HF. Indeed, it has been demonstrated in cell 
culture that Gal-3 turns quiescent fibroblasts into myofibroblasts that produce and 
secrete matrix proteins, including collagens [13, 17]. Gal-3 exerts its effects during 
several other stages of fibrogenesis besides collagen production, such as collagen 
maturation, externalization, and cross-linking, which underscores the pivotal 
importance of Gal-3 in cardiovascular fibrosis. Moreover, Gal-3 has emerged as a 
potential mediator of cardiac damage in different pathological situations through 
its ability to stimulate key pro-inflammatory molecules [16]. Thus, it has been 
demonstrated that in human cardiac fibroblasts, Gal-3 enhances the production and 
the secretion of pro-inflammatory and profibrotic mediators such as interleukin 
(IL)-1β, IL-6, CCL-2, collagen type I, collagen type III, and fibronectin as well as 
the activity of MMP-1, MMP-2, and MMP-9 [18]. The in vitro findings have been 
corroborated by animal studies. Thus, Gal-3 administration induces cardiac fibrosis 
leading to cardiac dysfunction in rats [13]. Additionally, a new line of evidence 
points out that Gal-3 is involved in reactive oxygen species (ROS) production, 
although the mechanisms have not been elucidated. Gal-3 increases the expression 
of Nox4 in cardiac cells and could regulate Nox4-derived ROS levels during cardiac 
fibrosis [19]. Moreover, Gal-3 downregulates peroxiredoxin-4 inducing a decrease 
in total antioxidant capacity and a consequent increase in peroxide production 
and in oxidative stress markers in cardiac fibroblasts [20]. Additionally, Gal-3 
downregulates the protective fumarate hydratase increasing fumarate production in 
human cardiac fibroblasts, leading to increased ROS levels and increased collagen 
production [21].
2.2 Galectin-3 as a mediator of Aldo/MR activation
Preclinical studies have demonstrated that Gal-3 is a key mediator of cardio-
vascular and renal fibrosis and dysfunction in pathological conditions associated 
with high Aldo levels [14, 18, 22–24]. In addition, hyperaldosteronism worsens 
hypertension-induced cardiovascular fibrosis through an increase of Gal-3 [25]. A 
summary of Gal-3 mediating Aldo/MR effects is shown in Figure 2.
2.2.1 Aldosterone/MR regulates galectin-3 expression in vitro
In vitro, in primary cultured vascular smooth muscle cells (VSMCs), Calvier 
and co-workers described that Aldo increases Gal-3 expression in a dose- and 
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time-dependent manner via its MR [14]. Gal-3, via its lectin activity, is a necessary 
mediator allowing Aldo-induced collagen type I synthesis, because the blockade of 
Gal-3 with carbohydrates such as modified citrus pectin (MCP, a complex water-
soluble indigestible polysaccharide rich in β-galactose) or N-Acetyl-D-lactosamine 
abolishes Aldo-induced collagen type I deposition. In confirmation of the phar-
macological data, Gal-3-depleted VSMCs are resistant to Aldo profibrotic effects, 
especially collagen type I deposition [14].
In human cardiac fibroblasts, Aldo also increased Gal-3 expression via its MR, 
and Gal-3 and Aldo enhance pro-inflammatory and profibrotic markers, as well as 
metalloproteinase activities, those effects being not observed in Gal-3-silenced cells 
treated with Aldo [18].
In line with these observations, it has been described that Aldo induces Gal-3 
secretion in inflammatory cells (macrophage cell lines THP-1 and RAW 264.7 cells) 
through MR and via PI3K/Akt and NF-kB transcription signaling pathways [26], 
amplifying the inflammatory response.
Finally, unpublished data from our group confirmed Gal-3 induction by Aldo via 
MR in other cell types such and renal cells and 3T3-L1 adipocytes.
2.2.2  Beneficial effects of galectin-3 blockade in experimental models with high 
aldosterone
In vivo, it has been shown that rats treated with Aldo-salt for 3 weeks pres-
ent hypertension and display vascular hypertrophy, inflammation, fibrosis, and 
increased aortic Gal-3 expression. Spironolactone or MCP treatment reverses all 
the above effects. Interestingly, MCP also blunts Aldo-induced hypertension. In 
Figure 2. 
Gal-3 as a mediator of Aldo/MR effects on fibrosis in several cells and tissues.
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wild-type (WT) and Gal-3 knockout (KO) mice treated with Aldo for 6 hours or 
3 weeks—a normotensive model—Aldo increases aortic Gal-3 expression, inflam-
mation, and collagen type I in WT mice at both the short- and the long-term, 
whereas no changes occur in Gal-3 KO mice. Altogether, these data show that 
Gal-3 is required for the inflammatory and fibrotic responses to Aldo in VSMCs 
in vivo, suggesting a key role for Gal-3 in vascular fibrosis [14]. While using the 
same experimental models, downstream in vitro experiments in human cardiac 
fibroblasts and the influence of Gal-3 on Aldo-mediated cardiac and renal effects 
have been also explored. Hypertensive Aldo-salt-treated rats present cardiac and 
renal hypertrophy (at morphometric, cellular, and molecular levels) and dysfunc-
tion. Cardiac and renal expressions of Gal-3 as well as levels of molecular markers 
attesting fibrosis are also augmented by Aldo-salt treatment. Spironolactone or 
MCP treatment reverses all of these effects. In WT mice, Aldo does not alter blood 
pressure levels but increases cardiac and renal Gal-3 expression, fibrosis, and renal 
epithelial-mesenchymal transition (i.e., renal epithelial cells differentiate onto 
extracellular matrix secreting and profibrotic myofibroblasts). Gal-3 KO mice are 
resistant to Aldo-induced deleterious cardiorenal effects [22].
Aldo levels are increased in spontaneously hypertensive rats (SHR) [27], as 
well as in hypertensive patients [28], being considered as an inducer of hyperten-
sive organ damage [29]. MR activation and high salt intake cause hypertension 
as well as inflammation, leading to cardiac inflammation and fibrosis [30]. Gal-3 
levels, as well as cardiorenal inflammation and fibrosis, are also increased in the 
myocardium and kidney from SHR as compared to normotensive controls. Gal-3 
pharmacological inhibition using MCP exerts beneficial effects,  diminishing 
cardiorenal inflammation and fibrosis in the absence of blood pressure 
 modifications [18, 23, 31].
Obesity is frequently associated with increased Aldo concentrations in humans 
[32] and is considered as HF stage A [33]. Obesity upregulates Gal-3 production 
in the cardiovascular and in the renal system in a normotensive animal model of 
diet-induced obesity by feeding for 6 weeks a high-fat diet, while Gal-3 inhibition 
with MCP reduces cardiovascular and renal levels of Gal-3, fibrosis, and inflam-
mation in obese animals without changes in body weight or blood pressure [34]. In 
adipose tissue, obese male Wistar rats fed with a high-fat diet for 6 weeks present an 
increase in Gal-3 levels that are accompanied by an increase in pericellular collagen. 
Obese rats exhibit higher adipose tissue inflammation, as well as enhanced dif-
ferentiation degree of the adipocytes. Treatment with MCP prevents all the above 
effects [24]. In summary, Gal-3 emerges as a potential therapeutic target in adipose 
tissue remodeling associated with obesity—a condition associated with hyperaldo-
steronemia—and could have an important role in the development of metabolic, 
cardiovascular, and renal alterations associated with obesity.
In theory, MR activation can promote aortic sclerosis and aortic stenosis (AS), 
due to its effect on inflammation and fibrosis. Once aortic valve disease has been 
established, the pressure or volume overload may induce left ventricular dysfunc-
tion. In a normotensive animal model of pressure overload (AS), cardiac, vascular, 
and renal Gal-3 is augmented, and its pharmacological inhibition with MCP 
prevents cardiovascular and renal functional alterations as well as cardiovascular 
and renal fibrosis and inflammation [21, 34, 35].
The acute administration of MRAs, either before the onset of ischemia or at the 
moment of reperfusion, profoundly reduces infarct size (reviewed in [36]). In an 
animal model of ischemia–reperfusion, cardiac Gal-3 is augmented, and its phar-
macological inhibition with MCP prevented cardiac functional, histological, and 
molecular alterations (unpublished data from our group).
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2.2.3 Aldosterone-galectin-3 in clinical populations
As mentioned above, Aldo increases Gal-3 expression in the cardiovascular and 
renal system as well as in adipose tissue in experimental models.
In a cohort of patients with Aldo-producing adenoma, the authors demonstrated 
that Gal-3 levels are enhanced. Interestingly, 1 year after adrenalectomy, plasma 
Gal-3 levels decrease, reinforcing the relation of Aldo-Gal-3 and confirming the 
results obtained using preclinical models [26]. In contrast with these observations, 
another group recently described that Gal-3 levels are not increased in patients with 
primary hyperaldosteronism (as compared to hypertensive patients) and levels do 
not decrease after adrenalectomy [37].
In untreated congestive HF, Aldo plasma concentrations are elevated in 
proportion to the severity of the disease and are further increased by the use of 
diuretic treatment [38]. Interestingly, the serum Gal-3 level has been correlated 
with serum markers of cardiac extracellular matrix turnover in HF patients, and, 
therefore, Gal-3 emerges as a biomarker associated with HF onset, morbidity, and 
mortality [39].
In morbidly obese patients presenting high Aldo levels, insulin resistance, and 
left ventricular hypertrophy, high Gal-3 levels are associated with a worsening of 
diastolic function [23]. Moreover, in patients with AS, cardiac Gal-3 is increased 
and associates with markers of myocardial fibrosis and inflammation [35]. 
Interestingly, both Aldo and Gal-3 are increased in pulmonary arterial hyperten-
sion patients. The axis Aldo/Gal-3 is relevant in pulmonary arterial hypertension 
because plasma levels of both molecules are associated with pulmonary arterial 
hypertension severity [40]. Furthermore, Gal-3 positively correlated with Nox4 
(related to oxidative stress production) in pulmonary arterial hypertension 
patients [41].
Given the intimate relation between Aldo, Gal-3, and cardiovascular fibrosis, 
the predictive value of Gal-3 in patients treated with MRAs has been analyzed. In a 
cohort of HF patients, MRA treatment does not alter the prognostic value of Gal-3 
[42]. An analysis examining the interaction between baseline Gal-3 levels and MRA 
therapy on outcomes shows no difference in patients who were receiving MRA [43]. 
Moreover, among patients with chronic HF and elevated Gal-3 concentrations, 
there is no specific benefit from addition or intensification of MRA therapy [44].
3. NGAL
3.1 NGAL induces fibrosis and inflammation
NGAL, also known as lipocalin-2, 24p3, siderocalin, or uterocalin, is a small 
glycoprotein of 25 kDa member of the lipocalin family. NGAL is expressed by dif-
ferent cell types including renal, endothelial, VSMCs, macrophages, dendritic cells, 
cardiomyocytes or cardiac fibroblasts (reviewed in [45]).
NGAL is involved in a wide variety of pathological situations as cardiovascular 
and renal diseases. Indeed, it has been demonstrated in cell culture that NGAL 
enhances the production and the secretion of pro-inflammatory and profibrotic 
mediators such as interleukin (IL)-1β, IL-6, CCL-2, osteopontin, collagen type I, 
and collagen type III in human cardiac fibroblasts [46, 47]. NGAL also increases 
collagen type I production as well as CT-1 and Gal-3 expression and secretion in 
VSMCs [48]. In cardiac cells, NGAL can also activate the inflammatory pathway 
NF-kB [47]. Moreover, NGAL treatment induces migration of neutrophils [49], 
and NGAL KO mice have been shown to present reduced chemotaxis and adhesion 
7Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets…
DOI: http://dx.doi.org/10.5772/intechopen.87232
[50]. Moreover, NGAL KO mice subjected to ischemia/reperfusion do not present 
immune cell recruitment [51].
3.2 NGAL as a mediator of Aldo/MR activation
In vitro, in HL-1 cardiomyocytes, Aldo induces NGAL expression via its MR 
[52]. These results have been also expanded to other cell types such as cardiac 
fibroblasts, where Aldo also enhances NGAL expression [47].
Preclinical studies have demonstrated that NGAL is a key mediator of cardiovas-
cular and renal fibrosis, inflammation, and dysfunction in pathological conditions 
associated with high Aldo levels. Firstly, NGAL has been found to be increased in 
mice overexpressing MR in cardiomyocytes [52]. Moreover, NGAL KO mice have 
been found to be resistant to Aldo-salt-induced hypertension and vascular fibrosis 
[48]. Interestingly, NGAL KO mice subjected to myocardial infarction show lower 
cardiac fibrosis and inflammation as well as improved cardiac function [47]. 
Recently it has been described using mice depleted for NGAL in their immune cells 
by bone marrow transplantation that NGAL from immune cells is mandatory for 
Aldo-induced cardiac fibrosis and inflammation [53].
In hypertensive patients, NGAL plasma concentrations are elevated and cor-
relate with blood pressure levels [54]. NGAL serum levels are also increased in myo-
cardial infarction patients and in HF patients [55, 56], as well as in obese patients 
[57]. Importantly, the rise of the complex NGAL/MMP-9 in obese subjects (stage A 
HF) and its association with plasma Aldo levels suggest that NGAL may serve as a 
biomarker of MR activation [48].
4. Cardiotrophin-1
4.1 Cardiotrophin-1 induces fibrosis and inflammation
CT-1 is a member of the interleukin-6 superfamily, which is expressed in 
different tissues including the heart, vessels, skeletal muscle, liver, lung, adipose 
tissue, and kidney [58, 59]. In the myocardium, CT-1 is produced by both cardio-
myocytes and fibroblasts, exerting its action through the glycoprotein 130 (gp130)/
leukemia inhibitory factor receptor (LIFR) heterodimer. Whereas CT-1 was initially 
described as a stress-response factor promoting cardiomyocyte survival [60], 
chronic exposure to this cytokine induces cardiomyocyte hypertrophy and dys-
function [61, 62]. In addition, experimental in vitro findings in rodent and canine 
fibroblasts [63–66] as well as in VSMCs [67] suggest that CT-1 behaves also as a 
profibrotic factor. In particular, CT-1 induces fibroblast growth and proliferation 
and collagen production. Moreover, in human cardiac fibroblasts, CT-1 has been 
shown to stimulate myofibroblast differentiation and collagen type I and III produc-
tion [68]. Coherently, rats chronically exposed to CT-1 present increased fibrosis 
in the cardiovascular and in the renal system characterized by increased collagen 
deposition [62]. Finally, data in chronic HF patients indicate that an association 
exists between CT-1 and collagen type I and III production in the myocardium [68].
4.2 Cardiotrophin-1 as a mediator of Aldo/MR activation
In vitro, in HL-1 cardiomyocytes, Aldo induces CT-1 in a dose- and time-dependent  
manner via its MR and through the activation of p38MAPK signaling pathway 
[69]. Moreover, Aldo also enhances CT-1 expression in VSMCs [67]. Interestingly, 
CT-1 blockade with specific antibodies avoids Aldo-induced hypertrophy of 
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cardiomyocytes. According to the in vitro data, CT-1-null mice subjected to acute 
Aldo treatment are resistant to Aldo-induced expression of hypertrophic markers 
[69]. These results were confirmed in other studies demonstrating that in experimen-
tal hyperaldosteronism, the increase of cardiac CT-1 expression is associated with 
parameters showing left ventricular hypertrophy and fibrosis. Moreover, CT-1-null 
mice are resistant to Aldo-induced left ventricular hypertrophy and fibrosis [70].
CT-1 expression has been found to be increased in the myocardium of HF 
patients of different etiologies [68, 71]. Importantly, and according to the results 
obtained in experimental models, in HF patients high Aldo levels are associated 
with high CT-1 levels [72].
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